Tag: Nirsevimab
-
Beyfortus (Nirsevimab) Arrives in Malaysia to Shield Infants from RSV
Malaysia Approves Beyfortus (Nirsevimab) to Guard Infants Against RSV In a move welcomed by pediatric health advocates, Beyfortus (Nirsevimab), the preventive monoclonal antibody developed by Sanofi and AstraZeneca, has been approved by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in infants. The approval…
-
Monoclonal Antibodies Shield Infants from RSV
RSV in Infants: A Critical Early Challenge Respiratory syncytial virus (RSV) is a common wintertime pathogen that most healthy adults weather with mild cold-like symptoms. For infants, especially those under six months, RSV can lead to bronchiolitis and pneumonia, sometimes necessitating hospital care. While vaccination strategies for other age groups exist, protecting newborns and very…
-
Monoclonal Antibody Protects Children from RSV: Real-World Evidence
Groundbreaking real-world evidence supports nirsevimab’s role against RSV In a significant step forward for pediatric infectious disease prevention, a large real-world study published in the Journal of Infection provides fresh evidence that the long-acting monoclonal antibody nirsevimab (Beyfortus) offers protection against respiratory syncytial virus (RSV) infection in children. The findings, drawn from diverse clinical settings,…
-
Monoclonal Antibody nirsevimab Beyfortus Shields Children from RSV
New Evidence Supports nirsevimab Beyfortus in RSV Prevention A comprehensive real-world study published in the Journal of Infection highlights the protective role of the long-acting monoclonal antibody nirsevimab, marketed as Beyfortus, against respiratory syncytial virus (RSV) in children. The findings add to the growing body of evidence that this preventive treatment can reduce RSV infections…
-
Monoclonal Antibody Protects Children from RSV: Real-World Insights
RSV’s Burden on Young Lungs Respiratory syncytial virus (RSV) remains a leading cause of hospitalization for infants and young children worldwide. While most kids recover with supportive care, a subset experiences severe disease that can require intensive care. In this context, scientists have been pursuing preventive strategies beyond vaccines, including long-acting monoclonal antibodies that offer…
-
Western Australia Faces Record RSV Season Despite Strong Immunisation Uptake
RSV in WA: A Record-Breaking Season Meets Strong Immunisation Western Australia is navigating what could be its worst respiratory syncytial virus (RSV) year on record. Latest health data show 11,551 RSV cases reported to the Department of Health as of Monday, just 104 cases shy of the peak set in 2022. While the numbers paint…
-
RSV in WA: Despite Strong Immunisation, Health Officials Fear Record Year
RSV in Western Australia: A record-chasing season despite high immunisation uptake Western Australia is approaching a potential record year for respiratory syncytial virus (RSV) cases, even as a broad immunisation program for infants and pregnant women helps blunt severe outcomes. Health authorities report 11,551 RSV notifications up to Monday, just 104 cases shy of the…
-
Bronchiolitis Update: Beyfortus Indication Expanded to 24 Months for Vulnerable Kids
What Beyfortus is and how it works Beyfortus, also known as nirsevimab, is a monoclonal antibody designed to protect young children from severe bronchiolitis caused by respiratory syncytial virus (RSV). Unlike vaccines, Beyfortus provides passive immunity through a single intramuscular injection that covers the upcoming RSV season, reducing the risk of hospitalization for RSV-related illness…
-
Bronchiolitis and Beyfortus: Expanded indication for vulnerable children up to 24 months
Overview: Beyfortus and the fight against RSV bronchiolitis Bronchiolitis is a common respiratory illness in young children, most notably caused by the respiratory syncytial virus (RSV). Protecting vulnerable infants and toddlers from severe RSV infections has long been a priority for pediatric care teams. Beyfortus, the synthetic antibody nirsevimab developed by AstraZeneca and marketed by…
-
Beyfortus Expanded: RSV Prophylaxis Up to 24 Months for Vulnerable Children
Overview of Beyfortus’ Expanded indication The Beyfortus (nirsevimab) monoclonal antibody, originally approved to protect infants against severe RSV infection, has had its indication widened. Regulators have approved its use in children up to 24 months who remain vulnerable to a severe RSV illness. This development extends access to a passive immunization approach that can help…